Chaim Putterman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3929962/publications.pdf

Version: 2024-02-01

163 papers	8,730 citations	36203 51 h-index	53109 85 g-index
171 all docs	171 docs citations	171 times ranked	7829 citing authors

#	Article	IF	Citations
1	The immune cell landscape in kidneys of patients with lupus nephritis. Nature Immunology, 2019, 20, 902-914.	7.0	501
2	Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nature Reviews Nephrology, 2015, 11, 329-341.	4.1	289
3	Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nature Immunology, 2019, 20, 915-927.	7.0	275
4	Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nature Reviews Rheumatology, 2019, 15, 137-152.	3.5	228
5	Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. Journal of Clinical Investigation, 2005, 115, 3428-3439.	3.9	219
6	Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 1955-1960.	3.3	190
7	Î±-Actinin Is a Cross-Reactive Renal Target for Pathogenic Anti-DNA Antibodies. Journal of Immunology, 2002, 168, 3072-3078.	0.4	187
8	Immunization with a Peptide Surrogate for Double-stranded DNA (dsDNA) Induces Autoantibody Production and Renal Immunoglobulin Deposition. Journal of Experimental Medicine, 1998, 188, 29-38.	4.2	184
9	PD-1hiCXCR5â€“ T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. JCI Insight, 2019, 4, .	2.3	171
10	Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis. JCI Insight, 2017, 2, .	2.3	164
11	Metabolic Disturbances Associated with Systemic Lupus Erythematosus. PLoS ONE, 2012, 7, e37210.	1.1	160
12	Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Research and Therapy, 2009, 11, R143.	1.6	156
13	Proinflammatory Effects of Tweak/Fn14 Interactions in Glomerular Mesangial Cells. Journal of Immunology, 2006, 176, 1889-1898.	0.4	155
14	Elevated Urinary VCAM-1, P-Selectin, Soluble TNF Receptor-1, and CXC Chemokine Ligand 16 in Multiple Murine Lupus Strains and Human Lupus Nephritis. Journal of Immunology, 2007, 179, 7166-7175.	0.4	148
15	TWEAK/Fn14 Interactions Are Instrumental in the Pathogenesis of Nephritis in the Chronic Graft-versus-Host Model of Systemic Lupus erythematosus. Journal of Immunology, 2007, 179, 7949-7958.	0.4	140
16	The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. Arthritis and Rheumatology, 2017, 69, 2006-2017.	2.9	126
17	Deficiency of Type I IFN Receptor in Lupus-Prone New Zealand Mixed 2328 Mice Decreases Dendritic Cell Numbers and Activation and Protects from Disease. Journal of Immunology, 2009, 183, 6021-6029.	0.4	122
18	Urinary TWEAK and the activity of lupus nephritis. Journal of Autoimmunity, 2006, 27, 242-250.	3.0	119

#	Article	IF	Citations
19	Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis and Rheumatism, 2007, 56, 1894-1903.	6.7	117
20	TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine, 2009, 46, 24-35.	1.4	112
21	BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis and Rheumatism, 2005, 52, 2080-2091.	6.7	110
22	Urinary Biomarkers in Lupus Nephritis. Clinical Reviews in Allergy and Immunology, 2011, 40, 138-150.	2.9	110
23	Role of TWEAK in lupus nephritis: A bench-to-bedside review. Journal of Autoimmunity, 2012, 39, 130-142.	3.0	110
24	Cross-reactivity of human lupus anti-DNA antibodies with ?-actinin and nephritogenic potential. Arthritis and Rheumatism, 2005, 52, 522-530.	6.7	105
25	The pathogenesis, diagnosis and treatment of lupus nephritis. Current Opinion in Rheumatology, 2014, 26, 502-509.	2.0	103
26	The role of TWEAK/Fn14 IN the pathogenesis of inflammation and systemic autoimmunity. Frontiers in Bioscience - Landmark, 2004, 9, 2273.	3.0	98
27	Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway. Journal of Autoimmunity, 2013, 43, 44-54.	3.0	96
28	Autoantibodies in lupus: Culprits or passive bystanders?. Autoimmunity Reviews, 2012, 11, 596-603.	2.5	95
29	Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology, 2010, 49, 960-971.	0.9	94
30	TWEAK and the progression of renal disease: clinical translation. Nephrology Dialysis Transplantation, 2014, 29, i54-i62.	0.4	94
31	TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice. Journal of Autoimmunity, 2015, 60, 40-50.	3.0	92
32	Deficiency of Fibroblast Growth Factor-Inducible 14 (Fn14) Preserves the Filtration Barrier and Ameliorates Lupus Nephritis. Journal of the American Society of Nephrology: JASN, 2015, 26, 1053-1070.	3.0	86
33	Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis. Arthritis Research and Therapy, 2012, 14, R164.	1.6	85
34	Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. Clinical Immunology, 2012, 145, 108-121.	1.4	84
35	Neuropsychiatric Lupus, the Blood Brain Barrier, and the TWEAK/Fn14 Pathway. Frontiers in Immunology, 2013, 4, 484.	2.2	80
36	Depression is an early disease manifestation in lupus-prone MRL/lpr mice. Journal of Neuroimmunology, 2009, 207, 45-56.	1.1	78

#	Article	IF	Citations
37	The MRL/lpr Mouse Strain as a Model for Neuropsychiatric Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-15.	3.0	77
38	A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine. Clinical Rheumatology, 2011, 30, 1385-1392.	1.0	74
39	Macrophage depletion ameliorates nephritis induced by pathogenic antibodies. Journal of Autoimmunity, 2015, 57, 42-52.	3.0	74
40	CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus. Clinical Immunology, 2017, 185, 100-108.	1.4	73
41	Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: Involvement of HMGB1 in anti-DNA antibody-induced renal injury. Immunology Letters, 2008, 121, 61-73.	1.1	72
42	Extracellular RNAs: development as biomarkers of human disease. Journal of Extracellular Vesicles, 2015, 4, 27495.	5.5	72
43	Nephritogenic Anti-DNA antibodies regulate gene expression in MRL/lprmouse glomerular mesangial cells. Arthritis and Rheumatism, 2006, 54, 2198-2210.	6.7	70
44	Measurement of cellâ€bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 4040-4047.	6.7	66
45	Association of Î±-actininâ€“binding antiâ€“double-stranded DNA antibodies with lupus nephritis. Arthritis and Rheumatism, 2006, 54, 2523-2532.	6.7	65
46	Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Science and Medicine, 2014, 1, e000056.	1.1	65
47	The blood brain barrier and neuropsychiatric lupus: new perspectives in light of advances in understanding the neuroimmune interface. Autoimmunity Reviews, 2017, 16, 612-619.	2.5	60
48	Molecular Analysis of the Autoantibody Response in Peptide-Induced Autoimmunity. Journal of Immunology, 2000, 164, 2542-2549.	0.4	59
49	Lipocalin-2, TWEAK, and Other Cytokines as Urinary Biomarkers for Lupus Nephritis. Annals of the New York Academy of Sciences, 2007, 1109, 265-274.	1.8	57
50	Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets. Journal of Allergy and Clinical Immunology, 2021, 148, 1281-1292.	1.5	57
51	The double edged sword of the immune response: mutational analysis of a murine anti-pneumococcal, anti-DNA antibody.. Journal of Clinical Investigation, 1996, 97, 2251-2259.	3.9	57
52	TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier. Journal of Neuroinflammation, 2013, 10, 9.	3.1	56
53	Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities. Nature Communications, 2020, 11, 2197.	5.8	55
54	TWEAK/Fn14 Signaling Involvement in the Pathogenesis of Cutaneous Disease in the MRL/lpr Model of Spontaneous Lupus. Journal of Investigative Dermatology, 2015, 135, 1986-1995.	0.3	52

#	Article	IF	Citations
55	Mechanisms of neuropsychiatric lupus: The relative roles of the blood-cerebrospinal fluid barrier versus blood-brain barrier. Journal of Autoimmunity, 2018, 91, 34-44.	3.0	50
56	Tertiary lymphoid structures in the choroid plexus in neuropsychiatric lupus. JCI Insight, 2019, 4, .	2.3	50
57	The novel role of neutrophil gelatinase-B associated lipocalin (NGAL)/Lipocalin-2 as a biomarker for lupus nephritis. Autoimmunity Reviews, 2008, 7, 229-234.	2.5	48
58	New approaches to the renal pathogenicity of anti-DNA antibodies in systemic lupus erythematosus. Autoimmunity Reviews, 2004, 3, 7-11.	2.5	47
59	Neuropsychiatric systemic lupus erythematosus persists despite attenuation of systemic disease in MRL/lpr mice. Journal of Neuroinflammation, 2015, 12, 205.	3.1	47
60	Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study. Seminars in Arthritis and Rheumatism, 2018, 47, 545-551.	1.6	47
61	The constant region contributes to the antigenic specificity and renal pathogenicity of murine anti-DNA antibodies. Journal of Autoimmunity, 2012, 39, 398-411.	3.0	46
62	International validation of a urinary biomarker panel for identification of active lupus nephritis in children. Pediatric Nephrology, 2017, 32, 283-295.	0.9	46
63	Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Sphingosine-1-Phosphate Signaling. Frontiers in Immunology, 2018, 9, 2189.	2.2	44
64	Excreted urinary mediators in an animal model of experimental immune nephritis with potential pathogenic significance. Arthritis and Rheumatism, 2007, 56, 949-959.	6.7	43
65	Lipocalin-2 is a pathogenic determinant and biomarker of neuropsychiatric lupus. Journal of Autoimmunity, 2019, 96, 59-73.	3.0	43
66	Intracerebroventricular administration of TNF-like weak inducer of apoptosis induces depression-like behavior and cognitive dysfunction in non-autoimmune mice. Brain, Behavior, and Immunity, 2016, 54, 27-37.	2.0	42
67	Antigenic triggers and molecular targets for anti-double-stranded DNA antibodies. Lupus, 2002, 11, 865-871.	0.8	40
68	Î±-Actinin Immunization Elicits Anti-Chromatin Autoimmunity in Nonautoimmune Mice. Journal of Immunology, 2007, 179, 1313-1321.	0.4	40
69	Therapeutic targeting of macrophages in lupus nephritis. Discovery Medicine, 2015, 20, 43-9.	0.5	40
70	Anti-alpha-actinin antibodies: A new marker of lupus nephritis. Autoimmunity Reviews, 2007, 6, 464-468.	2.5	39
71	Urine Proteome Scans Uncover Total Urinary Protease, Prostaglandin D Synthase, Serum Amyloid P, and Superoxide Dismutase as Potential Markers of Lupus Nephritis. Journal of Immunology, 2010, 184, 2183-2193.	0.4	39
72	BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis. Clinical Immunology, 2018, 197, 205-218.	1.4	39

#	Article	IF	Citations
73	Quantitative planar array screen of 1000 proteins uncovers novel urinary protein biomarkers of lupus nephritis. Annals of the Rheumatic Diseases, 2020, 79, 1349-1361.	0.5	39
74	Differential Binding of Cross-Reactive Anti-DNA Antibodies to Mesangial Cells: The Role of Î±-Actinin. Journal of Immunology, 2006, 176, 7704-7714.	0.4	38
75	TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis. Immunology Letters, 2009, 125, 119-128.	1.1	38
76	The Incidence and Prevalence of Adult Primary SjÃ¶gren's Syndrome in New York County. Arthritis Care and Research, 2019, 71, 949-960.	1.5	38
77	Urine Proteomics and Renal <scp>Singleâ€Cell</scp> Transcriptomics Implicate Interleukinâ€16 in Lupus Nephritis. Arthritis and Rheumatology, 2022, 74, 829-839.	2.9	38
78	Sex and autoantibody titers determine the development of neuropsychiatric manifestations in lupus-prone mice. Journal of Neuroimmunology, 2010, 229, 112-122.	1.1	37
79	Neutrophil gelatinaseâ€“associated lipocalin is instrumental in the pathogenesis of antibodyâ€mediated nephritis in mice. Arthritis and Rheumatism, 2012, 64, 1620-1631.	6.7	37
80	Highly selective inhibition of Brutonâ€™s tyrosine kinase attenuates skin and brain disease in murine lupus. Arthritis Research and Therapy, 2018, 20, 10.	1.6	37
81	Phoenix from the flames: Rediscovering the role of the CD40â€“CD40L pathway in systemic lupus erythematosus and lupus nephritis. Autoimmunity Reviews, 2020, 19, 102668.	2.5	35
82	Brief Report: Tubulointerstitial Damage in Lupus Nephritis: A Comparison of the Factors Associated With Tubulointerstitial Inflammation and Renal Scarring. Arthritis and Rheumatology, 2018, 70, 1801-1806.	2.9	34
83	Studies on the Structure, Regulation, and Pathogenic Potential of Anti-dsDNA Antibodies. Methods, 1997, 11, 70-78.	1.9	33
84	Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus. Current Opinion in Rheumatology, 2020, 32, 152-158.	2.0	33
85	Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Brutonâ€™s Tyrosine Kinase. Scientific Reports, 2016, 6, 26164.	1.6	32
86	The role of B cells and autoantibodies in neuropsychiatric lupus. Autoimmunity Reviews, 2016, 15, 890-895.	2.5	32
87	The constant region affects antigen binding of antibodies to DNA by altering secondary structure. Molecular Immunology, 2013, 56, 28-37.	1.0	31
88	3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine. Nature Communications, 2021, 12, 4447.	5.8	30
89	IgG3 deficiency extends lifespan and attenuates progression of glomerulonephritis in MRL/lpr mice. Biology Direct, 2012, 7, 3.	1.9	29
90	The Role of Anti-DNA Antibodies in the Development of Lupus Nephritis: A Complementary, or Alternative, Viewpoint?. Seminars in Nephrology, 2015, 35, 439-443.	0.6	29

#	Article	IF	Citations
91	A Distinct T Follicular Helper Cell Subset Infiltrates the Brain in Murine Neuropsychiatric Lupus. Frontiers in Immunology, 2018, 9, 487.	2.2	29
92	A Peptide DNA Surrogate Accelerates Autoimmune Manifestations and Nephritis in Lupus-Prone Mice. Journal of Immunology, 2002, 168, 3617-3626.	0.4	28
93	Cognitive dysfunction in autoimmune rheumatic diseases. Arthritis Research and Therapy, 2020, 22, 78.	1.6	28
94	Orbital mucosa-associated lymphoid tissue (MALT)-type lymphoma in a patient with relapsing polychondritis. Arthritis and Rheumatism, 2001, 44, 1713-1715.	6.7	27
95	B cell and/or autoantibody deficiency do not prevent neuropsychiatric disease in murine systemic lupus erythematosus. Journal of Neuroinflammation, 2016, 13, 73.	3.1	27
96	Diagnostic and prognostic tests in systemic lupus erythematosus. Best Practice and Research in Clinical Rheumatology, 2017, 31, 351-363.	1.4	27
97	A Novel Microglia-Specific Transcriptional Signature Correlates With Behavioral Deficits in Neuropsychiatric Lupus. Frontiers in Immunology, 2020, 11, 230.	2.2	27
98	Mimotopes for lupus-derived anti-DNA and nucleosome-specific autoantibodies selected from random peptide phage display libraries: facts and follies. Journal of Immunological Methods, 2005, 296, 83-93.	0.6	26
99	The CD6/ALCAM pathway promotes lupus nephritis via T cellâ€“mediated responses. Journal of Clinical Investigation, 2022, 132, .	3.9	25
100	What Is a Rheumatologist and How Do We Make One?. Arthritis Care and Research, 2016, 68, 1166-1172.	1.5	24
101	Anti-alpha-actinin antibodies are part of the anti-cell membrane antibody spectrum that characterize patients with lupus nephritis. Journal of Autoimmunity, 2015, 61, 54-61.	3.0	23
102	Urinary high-mobility group box-1 associates specifically with lupus nephritis class V. Lupus, 2016, 25, 1551-1557.	0.8	22
103	Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. Lupus Science and Medicine, 2019, 6, e000344.	1.1	22
104	NF-kB signaling in myeloid cells mediates the pathogenesis of immune-mediated nephritis. Journal of Autoimmunity, 2019, 98, 33-43.	3.0	22
105	Improving Outcomes in Patients with Lupus and Endâ€Stage Renal Disease. Seminars in Dialysis, 2013, 26, 590-596.	0.7	21
106	Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors. Arthritis and Rheumatology, 2015, 67, 2523-2535.	2.9	21
107	Biomarkers for kidney involvement in pediatric lupus. Biomarkers in Medicine, 2015, 9, 529-543.	0.6	20
108	SLE-keyÂ® rule-out serologic test for excluding the diagnosis of systemic lupus erythematosus: Developing the ImmunArray iCHIPÂ®. Journal of Immunological Methods, 2016, 429, 1-6.	0.6	18

#	Article	IF	Citations
109	Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Science and Medicine, 2018, 5, e000263.	1.1	18
110	Neurofilament light is a biomarker of brain involvement in lupus and primary SjÃ¶grenâ€™s syndrome. Journal of Neurology, 2021, 268, 1385-1394.	1.8	18
111	Neuropsychiatric Symptoms in Lupus. Psychiatric Annals, 2012, 42, 322-328.	0.1	18
112	Proliferative Glomerulonephritis in Lupus Patients With Human Immunodeficiency Virus Infection: A Difficult Clinical Challenge. Seminars in Arthritis and Rheumatism, 2010, 40, 201-209.	1.6	17
113	Novelties in the field of autoimmunity â€“ 1st Saint Petersburg congress of autoimmunity, the bridge between east and west. Autoimmunity Reviews, 2017, 16, 1175-1184.	2.5	17
114	Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. Arthritis Care and Research, 2020, 72, 233-242.	1.5	17
115	Serum autoantibodies in pristane induced lupus are regulated by neutrophil gelatinase associated lipocalin. Clinical Immunology, 2014, 154, 49-65.	1.4	16
116	<scp>F</scp>n14 deficiency protects lupusâ€prone mice from histological lupus erythematosusâ€like skin inflammation induced by ultraviolet light. Experimental Dermatology, 2016, 25, 969-976.	1.4	16
117	Age-associated changes in the circulating human antibody repertoire are upregulated in autoimmunity. Immunity and Ageing, 2020, 17, 28.	1.8	16
118	B7x/B7-H4 modulates the adaptive immune response and ameliorates renal injury in antibody-mediated nephritis. Clinical and Experimental Immunology, 2015, 179, 329-343.	1.1	14
119	A peptide mimic blocks the cross-reaction of anti-DNA antibodies with glomerular antigens. Clinical and Experimental Immunology, 2016, 183, 369-379.	1.1	14
120	Are lupus animal models useful for understanding and developing new therapies for human SLE?. Journal of Autoimmunity, 2020, 112, 102490.	3.0	13
121	Treatment of lupus nephritis: facing the era of immunotherapy. Panminerva Medica, 2008, 50, 235-45.	0.2	13
122	Biomarkers for CNS involvement in pediatric lupus. Biomarkers in Medicine, 2015, 9, 545-558.	0.6	12
123	Anti-DNA antibody mediated catalysis is isotype dependent. Molecular Immunology, 2016, 69, 33-43.	1.0	12
124	A Markov Multi-State model of lupus nephritis urine biomarker panel dynamics in children: Predicting changes in disease activity. Clinical Immunology, 2019, 198, 71-78.	1.4	12
125	Insulin-Like Growth Factor Binding Protein-4 as a Marker of Chronic Lupus Nephritis. PLoS ONE, 2016, 11, e0151491.	1.1	11
126	Anti-IFNAR treatment does not reverse neuropsychiatric disease in MRL/lpr lupus mice. Lupus, 2019, 28, 1510-1523.	0.8	10

#	Article	IF	Citations
127	New Roadmap for the Journey From Internist to Rheumatologist. Arthritis Care and Research, 2017, 69, 769-775.	1.5	9
128	The SLE-key test serological signature: new insights into the course of lupus. Rheumatology, 2018, 57, 1632-1640.	0.9	9
129	The bloodâ€“brain barrier, TWEAK, and neuropsychiatric involvement in human systemic lupus erythematosus and primary SjÃ¶grenâ€™s syndrome. Lupus, 2018, 27, 2101-2111.	0.8	8
130	The T Cell Receptor Repertoire in Neuropsychiatric Systemic Lupus Erythematosus. Frontiers in Immunology, 2020, 11, 1476.	2.2	8
131	Upregulation of Proinflammatory Bradykinin Peptides in Systemic Lupus Erythematosus and Rheumatoid Arthritis. Journal of Immunology, 2020, 205, 369-376.	0.4	8
132	Remodeling of Neurotransmission, Chemokine, and PI3K-AKT Signaling Genomic Fabrics in Neuropsychiatric Systemic Lupus Erythematosus. Genes, 2021, 12, 251.	1.0	8
133	Cell-bound complement activation products associate with lupus severity in SLE. Lupus Science and Medicine, 2020, 7, e000377.	1.1	7
134	Membrane attack complex (MAC) deposition in renal tubules is associated with interstitial fibrosis and tubular atrophy: a pilot study. Lupus Science and Medicine, 2022, 9, e000576.	1.1	7
135	Choroid Plexusâ€“Infiltrating T Cells as Drivers of Murine Neuropsychiatric Lupus. Arthritis and Rheumatology, 2022, 74, 1796-1807.	2.9	7
136	The role of anti-Î±-actinin antibodies in the pathogenesis and monitoring of lupus nephritis. Arthritis Research and Therapy, 2009, 11, 137.	1.6	6
137	Increased Education is Associated with Decreased Compliance in an Urban Multi-Ethnic Lupus Cohort. Journal of Clinical & Cellular Immunology, 2014, 05, .	1.5	6
138	Single-cell RNA sequencing for the study of lupus nephritis. Lupus Science and Medicine, 2019, 6, e000329.	1.1	6
139	Development of Murine Systemic Lupus Erythematosus in the Absence of BAFF. Arthritis and Rheumatology, 2020, 72, 292-302.	2.9	6
140	CXCL13 Neutralization Attenuates Neuropsychiatric Manifestations in Lupus-Prone Mice. Frontiers in Immunology, 2021, 12, 763065.	2.2	6
141	High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. Rheumatology, 2022, 61, 4335-4343.	0.9	6
142	<scp>Aptamerâ€Based</scp> Screen of Neuropsychiatric Lupus Cerebrospinal Fluid Reveals Potential Biomarkers That Overlap With the Choroid Plexus Transcriptome. Arthritis and Rheumatology, 2022, 74, 1223-1234.	2.9	6
143	TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2017, 52, 420-424.	0.6	5
144	A Multianalyte Assay Panel With Cellâ€Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatologyâ€“Classified Lupus. ACR Open Rheumatology, 2021, 3, 116-123.	0.9	5

#	Article	IF	Citations
145	Promise and complexity of lupus mouse models. Nature Immunology, 2021, 22, 683-686.	7.0	5
146	TWEAKing the Hippocampus: The Effects of TWEAK on the Genomic Fabric of the Hippocampus in a Neuropsychiatric Lupus Mouse Model. Genes, 2021, 12, 1172.	1.0	5
147	Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. Lupus Science and Medicine, 2021, 8, e000522.	1.1	5
148	Lupus Nephritis: Persistent Challenges, New Approaches. Clinical Immunology, 2017, 185, 1-2.	1.4	3
149	Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice. Lupus Science and Medicine, 2019, 6, e000313.	1.1	3
150	Methodological considerations in comparing access to Pre-emptive renal transplantation between SLE and other ESRD causes in the USRDS. Seminars in Arthritis and Rheumatism, 2019, 48, 678-685.	1.6	2
151	Single Cell RNA Sequencing in Human Disease: Renal, Pancreatic, and Viral Diseases. Advances in Experimental Medicine and Biology, 2020, 1255, 195-202.	0.8	2
152	Cognitive Impairment in Anti-Phospholipid Syndrome and Anti-Phospholipid Antibody Carriers. Brain Sciences, 2022, 12, 222.	1.1	2
153	THU0317â€…Tubuloinsterstial Damage Is An Independent Predictor of End Stage Renal Disease in Lupus Nephritis Patients with Mild To Moderate Renal Impairment. Annals of the Rheumatic Diseases, 2016, 75, 302.1-302.	0.5	1
154	ISN Nexus 2016 Symposia: Translational Immunology in Kidney Diseaseâ€”The Berlin Roadmap. Kidney International Reports, 2016, 1, 327-339.	0.4	1
155	AB0435â€…Immunosignature Technology Identifies Systemic Lupus Erythematosus from A Drop of Serum. Annals of the Rheumatic Diseases, 2016, 75, 1056.1-1056.	0.5	1
156	BTK inhibition modulates multiple immune cell populations involved in the pathogenesis of immune mediated nephritis. Clinical Immunology, 2021, 223, 108640.	1.4	1
157	Modifiable predictors of racial differences in gait velocity in an elderly urban cohort. Annals of the Rheumatic Diseases, 2011, 70, A93-A93.	0.5	0
158	Structure-Function in Antibodies to Double-Stranded DNA. , 2018, , 127-144.		0
159	Pathogenesis of Neuropsychiatric Lupus. , 2019, , 317-323.		0
160	4336 Renal Tubular Complement C9 Deposition is Associated with Renal Tubular Damage and Fibrosis in Lupus Nephritis. Journal of Clinical and Translational Science, 2020, 4, 144-144.	0.3	0
161	MO007A PHASE 1B MULTIPLE ASCENDING-DOSE STUDY OF A CD6 TARGETED THERAPY, ITOLIZUMAB, IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WITH OR WITHOUT ACTIVE PROLIFERATIVE LUPUS NEPHRITIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
162	OP0071â€…A pathogenic anti-dna antibody binds to alpha-actinin in renal mesangial cells. , 2001, , .		0

#	Article	IF	Citations
163	OP0217â€…A permeable blood-brain barrier is not required for neuropsychatric manifestations in sle and pss. , 2018, , .		0